Literature DB >> 19086432

[Case of orbital apex syndrome caused by invasive aspergillosis successfully treated during the diagnostic procedure by the use of voriconazole].

Akihiro Sugai1, Mutsuo Oyake, Maiko Umeda, Yoshitaka Umeda, Nobuya Fujita.   

Abstract

A 75-year-old woman developed loss of vision and decreased ocular motility in all directions. She exhibited a left orbital apex syndrome, accompanied by sphenoiditis and hypertrophic pachymeningitis. Voriconazole treatment was initiated on the basis of clinical suspicion, although use of the serum beta-D glucan had negative results and a biopsy was not performed. Five days later, the left eye movements started to improve, and at that time the use of the serum aspergillus galactomannan antigen proved to have positive results. Six months later, the patient was neurologically intact and stable, except for a lack of visual acuity in counting fingers. Earlier prognoses of invasive sino-orbital aspergillosis were dismal, especially when corticosteroid therapy was done before diagnosis. This case suggests the usefulness of antifungal agents during the diagnostic procedure even when localized invasive aspergillosis is not ruled out.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19086432     DOI: 10.5692/clinicalneurol.48.746

Source DB:  PubMed          Journal:  Rinsho Shinkeigaku        ISSN: 0009-918X


  3 in total

1.  Invasive sino-orbital fungal infections in immunocompetent patients: a clinico-pathological study.

Authors:  Namrata Gangaram Adulkar; Santhi Radhakrishnan; N Vidhya; Usha Kim
Journal:  Eye (Lond)       Date:  2019-02-14       Impact factor: 3.775

2.  Orbital aspergillosis: voriconazole - the new standard treatment?

Authors:  Derek H Ohlstein; Claudia Hooten; Javier Perez; Charles L Clark; Hazem Samy
Journal:  Case Rep Ophthalmol       Date:  2012-02-04

Review 3.  Orbital aspergillosis: a case report and review of the literature.

Authors:  Mael Lever; Benjamin Wilde; Roman Pförtner; Cornelius Deuschl; Oliver Witzke; Stefanie Bertram; Anja Eckstein; Peter-Michael Rath
Journal:  BMC Ophthalmol       Date:  2021-01-08       Impact factor: 2.209

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.